World Hemophilia Day is today, April 17, and this year’s chosen theme by the World Federation for Hemophilia (WFH) is “Equitable access for all: recognizing all bleeding disorders.” On its website, the WFH called for moving toward “a world where all people with inherited bleeding disorders have…

Several members of my family are diehard Purdue University basketball fans. This year was particularly exciting for them due to Purdue’s performance in the recent NCAA basketball tournament. During a gathering at their house on Easter Sunday, which included watching an important March Madness game, I gained insight…

Men with severe hemophilia who wore activity wristbands to self-manage their physical activity saw significant improvements in their physical health and were capable of spending more time on moderate-intensity physical activity, a small study from Spain has found. According to the researchers, these findings demonstrate that activity wristbands “can…

I remember having a malady that afflicts many during the last months of high school, college, or graduate school: senioritis. While it’s not a physical illness, this condition plagues many students as they near the end of their educational journeys, leading to absences and other problems. Senioritis is basically a…

What do AA batteries, binder clips, bread ties, lip balm, pens and pencils, pliers, a glue gun, and a measuring tape have in common? They’re all items in my kitchen junk drawer. It’s a chaotic place that holds them till they’re needed at a moment’s notice. I’m grateful that it’s…

Ixinity (trenonacog alfa) has been approved by the U.S. Food and Drug Administration (FDA) for use in children younger than 12 with hemophilia B. This label expansion by the FDA means that the factor IX (FIX) replacement therapy, sold by Medexus Pharmaceuticals, can now be used in…

TiumBio is preparing to launch a Phase 1b clinical trial to test TU7710, its experimental treatment to manage bleeding in people with hemophilia who have inhibitors, that is, neutralizing antibodies that can lower standard therapies’ effectiveness. “Our team has been developing TU7710 as an innovative hemophilia treatment option,”…

Last Friday started like any other day. I felt excited that I’d survived my first week back at work after an incredible vacation in Washington, D.C. I began to prepare a mental schedule to order my day. As I thought of the many things around the house that needed my…

I vividly remember the playground at Our Lady of Fatima Catholic School in Galena Park, Texas. The monkey bar dome was the place for the risk-takers, who climbed to the top and faced the ground. I preferred the swings, which catapulted the brave ones as they flew off in a…

Note: This story was updated March 28, 2024, to clarify the gene therapy delivers the mRNA of the Cas9 enzyme. Intellia Therapeutics is ending its collaborative agreement with Regeneron, which had the two companies working together in developing hemophilia B gene-editing therapies, according to a securities and exchange…